Related Experiment Video
Updated: Jun 14, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Kristian Galanti1,2, Mario Di Marino1,2, Davide Mansour1,2
1Department of Neuroscience, Imaging and Clinical Sciences, G. D'Annunzio University of Chieti-Pescara, 66100 Chieti, Italy.
Insights
Antithrombotic therapies (ATT) are crucial for preventing cardiovascular ischemic events. This review examines current ATT strategies, balancing efficacy with bleeding risk, to guide optimal patient management.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Cardiovascular diseases (CVDs) necessitate antithrombotic therapies (ATT) to prevent ischemic events.
- Balancing antithrombotic efficacy with bleeding risk is a key clinical challenge.
- Increasing CVD burden requires optimized, combined pharmacological approaches.
Purpose of the Study:
- To comprehensively review current antithrombotic strategies in cardiovascular disease management.
- To enhance a systematic approach for effective clinical decision-making.
- To explore future perspectives in antithrombotic research.
Main Methods:
- Review of pivotal studies establishing current evidence in antithrombotic therapy.
- Analysis of antithrombotic strategies across various cardiovascular conditions.
- Consideration of special populations and their unique therapeutic needs.
Main Results:
- Antithrombotic therapies include antiplatelet and anticoagulant agents.
- Combined ATT approaches are increasingly imperative due to overlapping CVD presentations.
- Optimizing ATT duration is critical for managing ischemic and bleeding risks.
Conclusions:
- A systematic approach to ATT is essential for effective CVD management.
- Current evidence supports nuanced pharmacotherapeutic pathways for balancing risks.
- Future research will focus on advancements in antithrombotic therapies and their application.
Abstract:
Antithrombotic therapies (ATT) play a pivotal role in the management of cardiovascular diseases, aiming to prevent ischemic events while maintaining a delicate balance with the patient's bleeding risk. Typically, ATT can be classified into antiplatelet and anticoagulant therapies. Their application spans a broad spectrum of cardiovascular conditions, ranging from ischemic heart disease to atrial fibrillation, encompassing venous thromboembolisms and innovative structural interventional cardiology procedures. The global burden of cardiovascular diseases is steadily increasing, often giving rise to overlapping clinical presentations. Accordingly, the adoption of combined pharmacological approaches becomes imperative, potentially disrupting the delicate equilibrium between ischemic and bleeding risk, thus leading to nuanced pharmacotherapeutic pathways. In this context, contemporary investigations strive to identify a convergence point that optimizes the duration of medical therapy while addressing the need for antithrombotic effects, especially in the context of ischemic heart disease. This review aims to comprehensively revisit the main antithrombotic strategies in cardiovascular diseases, with the intention of enhancing a systematic approach which is key for the effective clinical management of these patients. Also, the review will examine the most impactful studies that have established the groundwork for current scientific evidence, with acknowledgement of special populations. Finally, we will cast a gaze into the future of this dynamic and evolving research field, exploring forthcoming perspectives and advancements.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

